Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2929-2940

  Martin, Eric S ^a,b   Belmont, Peter J ^b   Sinnamon, Mark J ^c   Richard, Larissa Georgeon ^c   Yuan, Jing ^b   Coffee, Erin M ^c   Roper, Jatin ^c   Lee, Lydia ^c   Heidari, Pedram ^e   Lunt, Sophia Y ^d   Goel, Gautam ^e   Ji, Xiadong ^b   Xie, Zhi ^b   Xie, Tao ^b   Lamb, John ^b   Weinrich, Scott L ^b   VanArsdale, Todd ^b   Bronson, Roderick T ^a   Xavier, Ramnik J ^e   Vander Heiden, Matthew G ^d   Kan, Julie L C ^b   Mahmood, Umar ^e   Hung, Kenneth E ^c,f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEOME; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESEARCH; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE MUTATION; GLUCOSE METABOLISM; GLYCOLYSIS; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE K RAS; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; VALIDATION STUDY;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CLUSTER ANALYSIS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENES, APC; GENES, P53; GENOTYPE; GLUCOSE; HUMANS; LACTIC ACID; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878976471     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2307     Document Type: Article

References (46)

1. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010;16:2921-6.
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010;87:272-7.
3. Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology 2009;136:780-98.
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
5. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 2010;107:1565-70.
6. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS ONE 2011;6:e25132.
7. Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res 2007;67:8468-76. (Pubitemid 47437420)
8. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
9. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48-55. (Pubitemid 40070939)
10. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
11. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011;8:511-24.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
13. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-7. (Pubitemid 17075079)
14. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
15. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5.
16. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603.
17. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-24.
18. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011;477:526-8.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
20. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011;10:328-9.
21. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-58. (Pubitemid 47327410)
22. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007;447:966-71. (Pubitemid 46975753)
23. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010;17:547-59.
24. Faca V, Krasnoselsky A, Hanash S. Innovative proteomic approaches for cancer biomarker discovery. Biotechniques 2007;43:279, 81-3, 85.
25. Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, et al. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. Cancer Prev Res (Phila) 2009;2:224-33.
26. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res 2007;67:10736-43. (Pubitemid 350145900)
27. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
28. Uronis JM, Threadgill DW. Murine models of colorectal cancer. Mamm Genome 2009;20:261-8.
29. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-3.
30. Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A 1991;88:9345-9. (Pubitemid 21915628)
31. Tseng W, Leong X, Engleman E. Orthotopic mouse model of colorectal cancer. J Vis Exp 2007;10:484.
32. Zigmond E, Halpern Z, Elinav E, Brazowski E, Jung S, Varol C. Utilization of murine colonoscopy for orthotopic implantation of colorectal cancer. PLoS ONE 2011;6:e28858.
33. Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011;71:5818-26.
34. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
35. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identi fies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
36. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 2010;120:3940-52.
37. Naik G. Scientists' elusive goal: reproducing study results. Wall Street Journal; 2011 [cited 2011 Dec 2]. Available from: http://online.wsj.com/article/ SB10001424052970203764804577059841672541590.html.
38. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64.
39. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5. (Pubitemid 17038084)
40. Fan Y, Dickman KG, Zong WX. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 2010;285:7324-33.
41. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science 2006;312:1650-3. (Pubitemid 43902663)
42. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-Dglucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-5. (Pubitemid 10034639)
43. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
44. Neuzil J, Rohlena J, Dong LF. K-Ras and mitochondria: dangerous liasons. Cell Res 2012;22:285-7.
45. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9. (Pubitemid 39472955)
46. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005;65:177-85. (Pubitemid 40070808)